bluebird bio (BLUE) – FDA
-
bluebird bio (BLUE) Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy
-
bluebird bio (BLUE) Reports Follow-up Data From Gene Therapy Program in Sickle Cell Disease Supporting Durable, Potentially Curative Benefits
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to BLUE Stock Lookup